Since the company’s inception in 1984, it is estimated that CryoLife’s products and tissues have been implanted in over 1 million patients worldwide.
CryoLife is headquartered in Kennesaw, Georgia, 20 miles northwest of Atlanta, with offices in Austin, Texas and Guildford, Surrey, UK, as well as sales and marketing centers in Germany and Singapore, and representation in over 85 countries worldwide.
The firm’s 700 employees hail from 11 countries and speak 17 languages. CryoLife’s staff includes four full-time physicians and seven Ph.D.s, with disciplines in chemical engineering, biomedical engineering, biochemistry, protein chemistry and organic chemistry.
CryoLife is a public company and is traded on the New York Stock Exchange under the symbol CRY.
